EnteroMedics Inc. (NASDAQ:ETRM) retreated -22.06% and closed its last session at $0.05. The stock has the market capitalization of $5.98 Million with the total outstanding shares of 112.86 Million. EnteroMedics Inc.. has Analysts’ Mean Recommendation of 2 between the scale of 1 to 5 (1 represents Strong Buy and 5 means Sell). The stock currently has P/E of 0 for trailing twelve months while its Forward P/E is 0.
EnteroMedics Inc. (NASDAQ:ETRM) touched its 52-Week High of $2.7 on Dec 31, 2015 while it’s 52-Week Low of $0.04 on Nov 22, 2016. The company currently has Return on Assets of -197.6 percent, Return on Equity of 0% and Return on Investment of -568.7 percent. The stock currently showing Weekly Volatility of 33.40%% and Monthly Volatility of 29.24% Percent with Average True Range of 0.02 and Beta of 2.24.
The 2 analysts offering 12-month price forecasts for EnteroMedics Inc have a median target of 1.10, with a high estimate of 2.00 and a low estimate of 0.20. The median estimate represents a +1,975.47% increase from the last price of 0.05.
The Company on 30 November declared that it will host a vBloc® Therapy commercialization and corporate update conference call today at 11:00 AM Eastern Time ahead of the Company’s anticipated special meeting of shareholders to be held Monday, December 12, 2016. The call will be led by Dan W. Gladney, the Company’s President, Chief Executive Officer and Chairman of the Board.
EnteroMedics Inc. was established to develop and commercialize a new therapeutic platform for treating a wide range of acute and chronic diseases that are mediated by the vagal nerves. Due to the large unmet need for more effective surgical management of obesity, and following an in-depth analysis of how the vagus nerve affects food intake and processing, EnteroMedics has selected obesity management as its primary focus.